journal article·2018-01-17

Theranostic Nanoplatform: Triple-Modal Imaging-Guided Synergistic Cancer Therapy Based on Liposome-Conjugated Mesoporous Silica Nanoparticles

Qi Sun, Qing You, Jinping Wang, Li Liu, Yidan Wang, Yilin Song, Yu Cheng, Siyu Wang, Fengping Tan, Nan Li

Publisher page

Abstract

Mesoporous silica nanoparticles (MSNs) have long since been investigated to provide a versatile drug-delivery platform due to their multitudinous merits. Presently, gadolinium (Gd), a T1 magnetic resonance imaging (MRI) contrast agent, was doped into MSNs as a newly emerging theranostic nanocomposite, which has received much research attention. However, it is still concerned about the dispersibility and drug leakage of MSNs. Hence, in this project, we constructed an near-infrared (NIR) irradiation-triggered, triple-modal imaging-guided nanoplatform based on doxorubicin (DOX)@Gd-doped MSNs, conjugating with indocyanine green (ICG)-loaded thermosensitive liposomes (designated as DOX@GdMSNs-ICG-TSLs). In this platform, ICG could contribute to both photodynamic therapy and photothermal therapy effects; meanwhile, it could also give play to near-infrared fluorescence imaging (NIRFI) as well as photoacoustic imaging (PAI). Consequently, NIRFI and PAI from ICG combined with the MRI function of Gd, devoted to triple-modal imaging with success. At the same time, folic acid-modified thermosensitive liposomes were explored to be coated onto the surface of DOX@GdMSNs, to solve the DOX leakage as well as improve cellular uptake. Under NIR irradiation, ICG could generate heat, thus leading to the rupture of ICG-TSLs and the release of DOX. Accordingly, the multifunctional nanocomposite appeared to be a promising meritorious theranostic nanoplatform to pave a way for treating cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Key Laboratory of Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Application Foundation and Cutting-edge Technologies Research Project of Tianjin · Peiyang Young Talent Fund, Tianjin University

References (44)

Show source-provided references
1. 10.1016/j.biomaterials.2016.08.04010.1016/j.biomaterials.2016.08.040 ↗
2. 10.1039/C6NR03398A10.1039/C6NR03398A ↗
3. 10.1002/adma.20150646010.1002/adma.201506460 ↗
4. 10.1039/c2cs15260f10.1039/c2cs15260f ↗
5. 10.1016/j.biomaterials.2017.01.02110.1016/j.biomaterials.2017.01.021 ↗
6. 10.1023/A:100860362254310.1023/A:1008603622543 ↗
7. 10.1021/cm402592t10.1021/cm402592t ↗
8. 10.1021/ja901831u10.1021/ja901831u ↗
9. 10.1007/s10971-017-4330-210.1007/s10971-017-4330-2 ↗
10. 10.1021/nn901376h10.1021/nn901376h ↗
11. 10.1016/j.actbio.2016.05.01210.1016/j.actbio.2016.05.012 ↗
12. 10.1021/ar300098610.1021/ar3000986 ↗
13. 10.1038/nmat299210.1038/nmat2992 ↗
14. 10.1016/j.biomaterials.2013.06.04210.1016/j.biomaterials.2013.06.042 ↗
15. 10.1002/anie.20080246910.1002/anie.200802469 ↗
16. 10.1016/j.biomaterials.2011.10.01710.1016/j.biomaterials.2011.10.017 ↗
17. 10.1002/anie.20060473810.1002/anie.200604738 ↗
18. 10.1002/adfm.20160374910.1002/adfm.201603749 ↗
19. 10.1016/j.saa.2017.03.03310.1016/j.saa.2017.03.033 ↗
20. 10.1038/nm.272110.1038/nm.2721 ↗
21. 10.1021/acsbiomaterials.6b0046210.1021/acsbiomaterials.6b00462 ↗
22. 10.1021/jp209055t10.1021/jp209055t ↗
23. 10.1016/j.biomaterials.2011.08.05310.1016/j.biomaterials.2011.08.053 ↗
24. 10.1016/j.biomaterials.2010.11.02810.1016/j.biomaterials.2010.11.028 ↗
25. 10.1002/smll.20160109410.1002/smll.201601094 ↗
26. 10.1021/acsami.7b0262210.1021/acsami.7b02622 ↗
27. 10.1039/C0NR00781A10.1039/C0NR00781A ↗
28. 10.1016/j.biomaterials.2017.05.01910.1016/j.biomaterials.2017.05.019 ↗
29. 10.1002/advs.20160010610.1002/advs.201600106 ↗
30. 10.1016/j.bmcl.2012.10.04410.1016/j.bmcl.2012.10.044 ↗
31. 10.1039/C6TB00799F10.1039/C6TB00799F ↗
32. 10.1021/acs.chemrev.5b0014010.1021/acs.chemrev.5b00140 ↗
33. 10.1021/cr400532z10.1021/cr400532z ↗
34. 10.1038/sj.clpt.610040010.1038/sj.clpt.6100400 ↗
35. 10.2147/IJN.S13053910.2147/IJN.S130539 ↗
36. 10.7150/thno.817110.7150/thno.8171 ↗
37. 10.7150/thno.663010.7150/thno.6630 ↗
38. 10.1038/srep1425810.1038/srep14258 ↗
39. 10.1016/j.nano.2016.05.01310.1016/j.nano.2016.05.013 ↗
40. 10.1007/s13346-017-0380-910.1007/s13346-017-0380-9 ↗
41. 10.1021/acs.nanolett.6b0539610.1021/acs.nanolett.6b05396 ↗
42. 10.1002/mabi.20160011910.1002/mabi.201600119 ↗
43. 10.1021/cr900266s10.1021/cr900266s ↗
44. 10.1615/CritRevBiomedEng.v34.i6.2010.1615/CritRevBiomedEng.v34.i6.20 ↗